Sepsis pp 41-52 | Cite as

Severe Community-Acquired Pneumonia

  • Marcos I. Restrepo
  • Eric M. Mortensen
  • Antonio Anzueto
Chapter

Abstract

Severe community-acquired pneumonia is a clinical diagnosis with significant impact on healthcare management around the world, with the highest morbidity and mortality of all the forms of community-acquired pneumonia. Severe pneumonia patients usually require intensive care unit management, including vasopressors and/or mechanical ventilation. Early clinical suspicion and prompt empiric antimicrobial therapies are mandatory in patients with severe pneumonia. A number of recent studies and guidelines addressing these issues have been published. They are reviewed in this article.

Keywords

Intensive Care Unit Admission Severe Acute Respiratory Syndrome Acute Respiratory Failure Respir Crit Severe Acute Respiratory Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pneumonia and influenza death rates: United States, 1994. Morb Mortal Wkly Rep 1995; 44: 535–7.Google Scholar
  2. 2.
    National Center for Health Statistics, Centers for Disease Control and Prevention: Advance report of final mortality statistics 1992. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, 1994.Google Scholar
  3. 3.
    Marston BJ, Plouffe JF, File TM Jr., et al., for the Community-Based Pneumonia Incidence Study Group. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157: 1709–18.PubMedCrossRefGoogle Scholar
  4. 4.
    Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.PubMedGoogle Scholar
  6. 6.
    European Study on Community-Acquired Pneumonia (ESOCAP) Committee. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986–91.CrossRefGoogle Scholar
  7. 7.
    Huchon, G, Woodhead M. Management of adult community-acquired lower respiratory tract infections. Eur Respir Rev 1998; 8: 391–426.Google Scholar
  8. 8.
    Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383–421.PubMedCrossRefGoogle Scholar
  9. 9.
    Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000; 160: 1399–1408.PubMedCrossRefGoogle Scholar
  11. 11.
    Dean NC, Suchyta MR, Bateman KA, et al. Implementation of admission decision support for community-acquired pneumonia. Chest 2000; 117: 1368–77.PubMedCrossRefGoogle Scholar
  12. 12.
    Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749–55.PubMedCrossRefGoogle Scholar
  14. 14.
    Ewig S, Schafer H, Torres A: Severity assessment in community-acquired pneumonia. Eur Respir J 2000; 16: 1193–201.PubMedCrossRefGoogle Scholar
  15. 15.
    Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158: 1102–08.PubMedGoogle Scholar
  16. 16.
    The British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993;49:346–50.Google Scholar
  17. 17.
    Cordero E, Pachon J, Rivero A, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: Validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med 2000; 162: 2063–8.PubMedGoogle Scholar
  18. 18.
    Pascual FE, Matthay MA, Bacchetti P, et al. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 2000; 117: 503–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20: 14–9.PubMedGoogle Scholar
  20. 20.
    El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163: 645–51.PubMedGoogle Scholar
  21. 21.
    Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: The Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117: 1017–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: Etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118: 1344–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Meehan TP, Chua-Reyes JM, Tate J, et al. Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 2000; 117: 1378–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Chien JW, Johnson JL. Viral pneumonias. Epidemic respiratory viruses. Postgrad Med 2000;107:41–2, 45–7, 51–2.Google Scholar
  25. 25.
    Ramos MM, Overturf GD, Crowley MR. Infection with sin nombre hantavirus: Clinical presentation and outcome in children and adolescents. Pediatrics 2001; 108: E27.PubMedCrossRefGoogle Scholar
  26. 26.
    Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines. Thorax 2001; 56: 296–301.PubMedCrossRefGoogle Scholar
  27. 27.
    Birch C, Gowardman J. Streptococcus pyogenes: A forgotten cause of severe community-acquired pneumonia. Anaesth Intensive Care 2000; 28: 87–90.PubMedGoogle Scholar
  28. 28.
    CDC. Update: outbreak of severe acute respiratory syndrome worldwide, 2003. MMWR 2003; 52: 241–8.Google Scholar
  29. 29.
    World Health Organization. Cumulative number of reported cases of severe acute respiratory syndrome (SARS). http://www.who.int/csr/sarscountry/2003.
  30. 30.
    Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 2003, in press.Google Scholar
  31. 31.
    Poutamen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348: 1995–2005.CrossRefGoogle Scholar
  32. 32.
    Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986–1994.PubMedCrossRefGoogle Scholar
  33. 33.
    Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1977–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Leroy O, Santre C, Beuscart C. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care Med 1995; 21: 24–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Moine P, Vercken JB, Chevret S, et al. Severe community-acquired pneumonia: Etiology, epidemiology, and prognosis factors. Chest 1994; 105: 1487–95.PubMedCrossRefGoogle Scholar
  36. 36.
    Tones A, Serra-Battles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–18.CrossRefGoogle Scholar
  37. 37.
    Manie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000; 31: 106678.Google Scholar
  38. 38.
    Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33: 797–805.PubMedCrossRefGoogle Scholar
  39. 39.
    Kahn M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840–7.CrossRefGoogle Scholar
  40. 40.
    Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Mehta R, Groth M. Clinical application of a prognostic model for severe community-acquired pneumonia. Chest 2001; 119: 312–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837–42.PubMedCrossRefGoogle Scholar
  43. 43.
    Burgess DS, Lewis JS II. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22: 872–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562–72.PubMedCrossRefGoogle Scholar
  45. 45.
    Martinez JA, Horcajada JP, Almela M. et al. Addition of a macrolide to a ß-lactambased empirical antibiotic regimen is associatred with lower mortality for patients with bacteremic pnuemococcal pneumonia. Clin Infect Dis 2003; 36: 389–95.PubMedCrossRefGoogle Scholar
  46. 46.
    Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001; 119: 1439–48.PubMedCrossRefGoogle Scholar
  47. 47.
    Halley HJ. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health Syst Pharm 2000; 57 (Suppl 3): S17–21.PubMedGoogle Scholar
  48. 48.
    Yost NP, Bloom SL, Richey SD, et al. An appraisal of treatment guidelines for antepartum community-acquiredpneumonia. Am J Obstet Gynecol 2000; 183: 131–5.PubMedGoogle Scholar
  49. 49.
    Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000; 22: 250–64.PubMedCrossRefGoogle Scholar
  50. 50.
    Fogarty CM, Greenberg RN, Dunbar L, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: Integrated results from 4 open-label, multicenter, phase III clinical trials. Clin Ther 2001; 23: 425–39.PubMedCrossRefGoogle Scholar
  51. 51.
    Clark LC, Davis CW. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Am J Health Syst Pharm 2000; 57 (Suppl 3): S10–3.PubMedGoogle Scholar
  52. 52.
    Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: Causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 1540.Google Scholar
  53. 53.
    Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001; 161: 61–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Arch Intern Med 2001; 161: 848–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: A meta-analysis. Arch Intern Med 2001; 161: 722–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Wunderink R, Leeper K Jr, Schein R, et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119: 523–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709.PubMedCrossRefGoogle Scholar
  58. 58.
    Tobin MJ. Advances in mechanical ventilation. N Engl J Med 2001; 344: 1986–96.PubMedCrossRefGoogle Scholar
  59. 59.
    Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 13349.CrossRefGoogle Scholar
  60. 60.
    The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–8.Google Scholar
  61. 61.
    Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160: 158591.Google Scholar
  62. 62.
    Navalesi P, Pollini A. Acute respiratory failure in patients with severe community-acquired pneumonia: A prospective, randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 2000; 162: 761–2.PubMedGoogle Scholar
  63. 63.
    Jolliet P, Abajo B, Pasquina P, et al. Noninvasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med 2001; 27: 812–21.PubMedCrossRefGoogle Scholar
  64. 64.
    Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 2001; 344: 481–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Meduri GU, Turner RE, Abou-Sala N, et al. Noninvasive positive pressure ventilation via face mask. First-line intervention in patients with acute hypercapnic and hypoxemic respiratory failure. Chest 1996; 109: 179–93.PubMedCrossRefGoogle Scholar
  66. 66.
    Conti G, Marino P, Cogliati A, et al. Noninvasive ventilation for the treatment of acute respiratory failure in patients with hematologic malignancies: A pilot study. Intensive Care Med 1998; 24: 1283–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Antonelli M, Conti G, Bufi M, et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: A randomized trial. JAMA 2000; 283: 235–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Marcos I. Restrepo
  • Eric M. Mortensen
  • Antonio Anzueto

There are no affiliations available

Personalised recommendations